Type 1 Diabetes TrialNet: A multifaceted approach to bringing disease-modifying therapy toclinical use in type 1 diabetes

Polly J. Bingley, Diane K. Wherrett, Ann Shultz, Lisa Rafkin, Mark A. Atkinson, Carla J. Greenbaum

Research output: Contribution to journalReview article

7 Scopus citations


What will it take to bring disease-modifying therapy to clinical use in type 1 diabetes? Coordinated efforts of investigators involved in discovery, translational, and clinical research operating in partnership with funders and industry and in sync with regulatory agencies are needed. This Perspective describes one such effort, Type 1 Diabetes TrialNet, a National Institutes of Health-funded and JDRFsupported international clinical trials network that emerged from the Diabetes Prevention Trial-Type 1 (DPT-1). Through longitudinal natural history studies, as well as trials before and after clinical onset of disease combined with mechanistic and ancillary investigations to enhance scientific understanDing and translation to clinical use, TrialNet is working to bring disease-modifying therapies to individuals with type 1 diabetes. Moreover, TrialNet uses its expertise and experience in clinical studies to increase efficiencies in the conduct of trials and to reduce the burden of participation on individuals and families. Herein, we highlight key contributions made by TrialNet toward a revised understanDing of the natural history of disease and approaches to alter disease course and outline the consortium's plans for the future.

Original languageEnglish (US)
Pages (from-to)653-661
Number of pages9
JournalDiabetes Care
Issue number4
StatePublished - Apr 1 2018


ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this